Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dakson-ORL** is a ready-to-use oral rehydration solution marketed by Emcee Pharmaceuticals for the prevention and treatment of dehydration associated with diarrhoea, vomiting, excessive sweating, and other fluid-loss states. It is a fixed-dose electrolyte and glucose formulation containing anhydrous dextrose, potassium chloride, sodium chloride, and sodium citrate; the components promote intestinal water and electrolyte uptake, replace lost sodium and potassium, and help correct dehydration-related acid-base imbalance. ([sastasundar.com](https://sastasundar.com/order-otc/dakson-orl-200-ml-rbn5nq9))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dakson-ORL.